Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies for people living with cancer. The XLO news feed on Stock Titan aggregates company-issued press releases and related coverage so readers can follow how Xilio’s pipeline, collaborations and financial position evolve over time.
News about Xilio frequently centers on clinical and preclinical data from its key programs. These include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab in advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in a Phase 1/2 trial for advanced solid tumors. The company also reports on progress for XTX501, a bispecific PD-1 / masked IL-2 molecule in IND-enabling studies, and multiple masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1.
Investors can use this page to track Xilio’s announcements about clinical trial milestones, data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), and updates on collaborations with partners including Gilead, Roche and AbbVie. The feed also captures corporate developments such as financings, warrant exercises, cash runway guidance, stock option plans and board or leadership changes disclosed in press releases and related SEC filings.
By reviewing the XLO news stream, readers gain a consolidated view of how Xilio’s masked immunotherapy platform is progressing through research and development, how external partners are engaging with its programs, and how the company is addressing Nasdaq listing requirements and capital needs as it advances its oncology pipeline.
Xilio Therapeutics (Nasdaq: XLO) granted inducement stock options effective April 1, 2026, to two new employees totaling 3,257 shares under its 2022 Inducement Stock Incentive Plan. The options carry an exercise price of $8.48 per share and a 10-year term.
Vesting: 25% on the first anniversary of employment, then the remaining 75% in 36 equal monthly installments, subject to continued service and plan/option agreement terms.
Xilio Therapeutics (Nasdaq: XLO) reported pipeline progress and Q4/full-year 2025 results. Key milestones include a planned XTX501 IND submission mid-2026, Phase 1 start H2 2026, candidate nomination for a multi-specific masked T cell engager in Q2 2026, and AACR data for a CLDN18.2 program in April 2026. Cash and cash equivalents were $137.5M at year-end, with an expected runway through end of 2027.
Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.
The poster, titled Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager, is scheduled for Monday, April 20, 2026, 9:00 a.m.–12:00 p.m. PST at Poster Section 10, Poster Board 11 (Abstract No. 1619).
Xilio Therapeutics (Nasdaq: XLO) will implement a 1-for-14 reverse stock split effective 5:00 p.m. ET on March 13, 2026, with split-adjusted trading beginning March 16, 2026 under ticker XLO and new CUSIP 98422T209. The split reduces outstanding shares from approximately 73.5 million to approximately 5.2 million.
The company said one primary goal is to increase its per-share market price to enable regaining compliance with Nasdaq Capital Market minimum bid price requirements. Warrants, equity awards and plan share pools will be proportionately adjusted; fractional shares will receive cash payments.
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO) granted non-qualified stock options to two new employees effective March 1, 2026 under its 2022 Inducement Stock Incentive Plan. The awards total 50,050 options with an exercise price of $0.5283 per share, equal to the February 27, 2026 closing price.
Each option has a ten-year term and vests 25% after one year, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service and plan terms.
Xilio Therapeutics (Nasdaq: XLO) priced an underwritten offering of 74,780,300 pre-funded warrants at $0.5349 each, exercisable for one share at $0.0001 per share. Gross proceeds are expected to be approximately $40.0 million, with closing on or about February 13, 2026, subject to customary conditions.
Investors include Coastlands Capital (lead), Gilead Sciences, OrbiMed, Perceptive Advisors and others. Leerink Partners is sole bookrunner. Net proceeds will be used to advance product development, working capital and general corporate purposes.
Xilio Therapeutics (NASDAQ: XLO) reported $35.8 million in gross proceeds from Series B warrant exercises and estimates $137.5 million in cash and cash equivalents as of December 31, 2025. The company said this funding extends its anticipated cash runway into the second quarter of 2027. Recent program updates include a development milestone for a masked antibody program under the AbbVie collaboration and nomination of a development candidate for a wholly owned masked T cell engager targeting CLDN18.2. Corporate changes include the appointment of Sara Bonstein as chair of the board. Anticipated next milestones include an IND submission for XTX501 in mid-2026 and initial Phase 1 data for XTX501 in H2 2027, subject to FDA clearance.
Xilio Therapeutics (Nasdaq: XLO) reported clinical and financial updates on Nov 13, 2025. At SITC, Phase 2 vilastobart data showed a 40% ORR in heavily pretreated, plasma TMB-high (≥10 mut/Mb) MSS mCRC patients without liver metastases, with p=0.05 correlation between plasma TMB and response. Phase 1 efarindodekin alfa monotherapy data showed promising anti-tumor activity and tolerability; XTX501 (bispecific PD-1/masked IL-2) is advancing toward a planned IND in mid-2026. Xilio presented preclinical masked T cell engager data and nominated a PSMA development candidate. Financials: $103.8M cash as of Sept 30, 2025; Q3 collaboration revenue $19.1M; net loss $16.3M. Company expects runway into Q1 2027.
Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase 2 data for vilastobart plus atezolizumab at SITC on Nov 7, 2025 showing a 40% objective response rate (ORR) in heavily pre-treated patients with MSS metastatic colorectal cancer (mCRC) who had no liver metastases and high plasma TMB (≥10 mut/Mb).
Data cutoff was May 12, 2025: 44 patients treated (100 mg Q6W vilastobart + 1200 mg Q3W atezolizumab), 27 without liver metastases, 24 evaluable for plasma TMB. Company estimates ~55% of non‑MSI‑H CRC are plasma TMB‑high. Responses included tumor reductions up to 71%. Safety: mostly Grade 1–2, 5% discontinued for treatment‑related AEs and 7% experienced colitis. Xilio will host a conference call/webcast on Nov 10, 2025 at 4:30 p.m. ET.